Oct 6, 2026 06:15AM
Oct 5, 2026 09:51AM
Oct 21, 2025 04:05PM
Oct 21, 2025 04:05PM
Aug 7, 2025 04:05PM
Sep 19, 2024 08:00AM
Aug 7, 2024 04:05PM Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
May 8, 2024 04:05PM
Feb 27, 2024 04:05PM
Feb 7, 2024 07:02AM
Feb 7, 2024 07:00AM
Nov 7, 2023 04:05PM
Oct 27, 2023 07:00AM
Sep 7, 2023 07:00AM Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Aug 3, 2023 04:05PM
Nov 29, 2022 11:08AM
Nov 29, 2022 11:05AM
Nov 29, 2022 11:05AM
Sep 9, 2022 05:34AM
Mar 15, 2022 08:01AM
Mar 15, 2022 08:00AM Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical Trial
Mar 15, 2022 08:00AM
Nov 12, 2021 01:51PM
Nov 12, 2021 01:50PM
Nov 12, 2021 01:50PM
Nov 10, 2021 08:30AM
Nov 10, 2021 08:30AM
Nov 4, 2021 04:05PM Alector Reports Third Quarter 2021 Financial Results
Nov 4, 2021 04:05PM
Sep 9, 2021 08:30AM
Sep 9, 2021 08:30AM
Jul 29, 2021 10:12AM
Jul 29, 2021 10:10AM
Jul 29, 2021 10:10AM
Jul 2, 2021 09:29AM Pre-Open Movers 07/02: (ALEC) (OSG) (SPCE) Higher; (ITRM) (DIDI) (BSGM) Lower (more...)
Jul 2, 2021 08:00AM
Jul 2, 2021 07:38AM
Jul 2, 2021 07:38AM
Jun 2, 2021 06:31AM
Jun 2, 2021 06:31AM
May 26, 2021 04:05PM
May 26, 2021 04:05PM Alector to Host Virtual Key Opinion Leader Event on Frontotemporal Dementia on June 11, 2021
Feb 25, 2021 04:05PM
Feb 25, 2021 04:05PM
Jul 29, 2020 05:53AM
Jul 28, 2020 06:00PM
Jul 28, 2020 06:00PM
Jul 24, 2020 08:34AM
Jul 24, 2020 08:30AM Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia
Jul 24, 2020 08:30AM

334,273 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All